Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novartis Discontinues Tasigna in GI Cancer | Contract Pharma

What are you searching for?

Sign in

Novartis Discontinues Tasigna in GI Cancer

Novartis AG is discontinuing development of Tasigna as a treatment for cancerous tumors of the gastrointestinal tract.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novartis AG is discontinuing development of Tasigna as a treatment for cancerous tumors of the gastrointestinal tract. According to the company, an independent data-monitoring committee recommended discontinuing a late-stage trial comparing Tasigna and Gleevec as a first-line treatment of gastrointestinal tumors after interim results showed that patients taking Tasigna were unlikely to live longer than those taking Gleevec, the current standard of care.

Tasigna is approved in the EU, Switzerland and Japan as a treatment for chronic myeloid leukemia.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters